CCS
BBH icon

Crosspoint Capital Strategies’s VanEck Biotech ETF BBH Stock Holding History

Crosspoint Capital Strategies’s Portfolio BBH Stock Details BBH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-145
Closed -$15K – 694
2014
Q3 		$15K Buy
+145
New +$14.7K 0.01% 333

Other funds holding BBH

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
MCM
Murphy Capital Management Bedminster, New Jersey $720M AUM 9.22% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BPC
Banque Pictet & Cie Geneva 73, Switzerland $14.2B AUM 20.68% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
LFM
Lumina Fund Management New York $164M AUM 27.72% 1-Year Est. Return

Crosspoint Capital Strategies's BBH Position: Q4 2014 in Review

Crosspoint Capital Strategies sold out of VanEck Biotech ETF (BBH) in Q4 2014, closing a stake of 145 shares — an estimated $15K sold.

Crosspoint Capital Strategies first reported a position in BBH in Q3 2014 and held it in 1 quarter. The position peaked at $15K in Q3 2014. 68 funds tracked by Wall St. Rank hold BBH as of Q4 2014.

  • Crosspoint Capital Strategies reported no remaining VanEck Biotech ETF position as of Q4 2014 after selling out during the quarter.
  • Crosspoint Capital Strategies sold 145 VanEck Biotech ETF shares in Q4 2014, an estimated $15K.
  • Crosspoint Capital Strategies first reported a position in VanEck Biotech ETF in Q3 2014 and held it in 1 quarter.
  • Crosspoint Capital Strategies's VanEck Biotech ETF position peaked at $15K in Q3 2014.
  • 68 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q4 2014.

Based on Crosspoint Capital Strategies's 13F filing for Q4 2014, filed 6 Mar 2015.